Snakebite envenomation (SBE) is a major public health issue in sub-Saharan Africa (SSA), particularly in Cameroon. This Phase IV, multicenter, open-label study was conducted from June 2024 to December 2024 to evaluate the safety and efficacy of PANAF-Premium™, a World Health Organization (WHO)-approved polyvalent antivenom that was introduced in Cameroon in 2023, given that prospectively gathered data and studies on this antivenom’s safety in SSA are limited. In total, 130 victims admitted to four district hospitals in North Cameroon with confirmed SBE were included. Data on envenomation syndromes, clinical outcomes, adverse events, and treatment response were recorded. Echis species were responsible for most bites, while clinical syndromes included hemotoxic (68.5%), cytotoxic (30.8%), and neurotoxic (0.8%) presentations. On average, victims required 3.34 vials and 5.55 days for clinical recovery. Early antivenom administration significantly reduced the number of antivenom vials required to manage the symptoms (p = 0.003) and hospital stay (p = 0.049). Seventeen patients experienced mild to moderate adverse events. Two deaths and a case of kidney injury were noted, all unrelated to antivenom use. These study findings indicate the safety and effectiveness of PANAF-Premium™ antivenom, meeting WHO performance targets. The results highlight the importance of timely antivenom administration in treating SBEs.
The rapid growth of clinical trials in sub-Saharan Africa (sSA) since 2010 has increased opportunities to evaluate interventions for children. However, children with common comorbidities—malnutrition, HIV infection, and sickle cell disease (SCD)—may be systematically excluded, limiting the applicability of trial findings. We quantified the extent of such exclusions and identified trial characteristics associated with exclusion. We analysed phase 2–4 interventional trials registered between 2010 and 2023 in ClinicalTrials.gov, the International Standard Randomized Controlled Trials Number, and the Pan-African Clinical Trials Registry. Eligibility criteria were reviewed and trials classified as including, excluding, probably including, or probably excluding each condition. Exclusion proportions were calculated among trials not primarily targeting these populations. Associations between exclusion and trial characteristics (phase, period, disease area, design, and intervention type) were examined. Among 1,276 trials, primary exclusion rates were 37.0% (95% CI: 34.3–39.7) for malnutrition, 41.2% (38.4–44.1) for HIV, and 35.1% (32.5–37.9) for SCD. Exclusion varied by trial phase, intervention type, and disease area. Children with these high-risk conditions remain substantially underrepresented in paediatric trials in sSA, undermining generalisability and equity. More inclusive trial designs are needed.